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Abstract
Children with hemodynamically significant congenital heart disease (CHD) are at elevated
risk of morbidity and mortality due to respiratory syncytial virus (RSV) disease compared to
their healthy peers. Previous studies have demonstrated lower RSV hospitalization risk
among all children with CHD at 12–23 months of age versus 0–11 months of age. However,
RSV hospitalization risk at 12–23 months of age by specific CHD diagnosis has not been
characterized. Both case-control and cohort studies were conducted using data from the US
National Inpatient Sample from 1997 to 2013 to characterize relative risk of RSV hospitaliza-
tion among children 12–23 months of age with CHD. Related CHD diagnoses were com-
bined for analysis. Hospitalizations for RSV and unspecified bronchiolitis were described by
length of stay, mechanical ventilation use, mortality, and total charges. Over the 17-year
period, 1,168,886 live birth hospitalizations with CHD were identified. Multiple specific CHD
conditions had an elevated odds ratio or relative risk of RSV hospitalization. Mean total RSV
hospitalization charges were significantly higher among children with CHD relative to those
without CHD ($19,650 vs $7,939 in 2015 dollars) for this period. Compared to children with-
out CHD, children with Ebstein’s anomaly, transposition of the great arteries, aortic stenosis,
heterotaxia, and aortic arch anomalies had 367-, 344-, 203-, 117- and 47-fold increased risk
of inpatient RSV mortality, respectively. Unspecified bronchiolitis hospitalization odds and
relative risk across CHD diagnoses were similar to those observed with RSV hospitalization;
however, unspecified bronchiolitis hospitalizations were associated with shorter mean days
of stay and less frequently associated with mechanical ventilation or mortality. Among chil-
dren with more severe CHD diagnoses, RSV disease remains an important health risk
through the second year of life. These data can help inform decisions regarding interven-
tions to protect children with CHD from severe RSV disease during their second year of life.
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Introduction
Respiratory syncytial virus (RSV) is a common pediatric respiratory infection, with nearly all
children affected by 2 years of age [1]. More than 170,000 children under 5 years of age are
hospitalized annually in the United States (US) due to RSV, with hospitalization rates highest
among children less than 1 year of age [2, 3]. Morbidity and mortality associated with RSV are
increased among certain populations, including children with hemodynamically significant
congenital heart disease [4–6]. When hospitalized, children with hemodynamically significant
CHD can experience a more complicated clinical course, with a high proportion requiring
intensive care unit admission, assisted ventilation, longer duration of oxygen supplementation,
and prolonged duration of hospital stay [7–10]. In addition, congenital heart disease (CHD)
has been associated with a 3.7-fold increased risk of death among infants hospitalized for RSV
[11].
Immunoprophylaxis with palivizumab has demonstrated reduced RSV-related hospitaliza-
tion in high-risk groups, including preterm infants35 weeks’ gestational age and children
24 months of age with bronchopulmonary dysplasia or hemodynamically significant CHD
[12, 13]. In a study of 1287 children24 months of age with hemodynamically significant
CHD, palivizumab was associated with a 45% relative reduction in RSV hospitalizations com-
pared with placebo (P = .003), a 56% reduction in days of RSV hospitalization per 100 children
(P = .003), and a 73% reduction in total RSV hospitalization days with increased supplemental
oxygen per 100 children (P = .014) [13]. A recent single-center case-control study demon-
strated a 75% reduction (P< .001) in lower respiratory tract infection (LRTI)-related hospitali-
zation, 65% reduction (P = .008) in LRTI-related intensive care unit admissions, and 49%
reduction (P = .02) in LRTI-related mortality in infants with CHD who received palivizumab
prophylaxis versus those who did not [14].
In 2003, the American Academy of Pediatrics (AAP) released a policy statement recom-
mending RSV immunoprophylaxis in children24 months of age with hemodynamically sig-
nificant cyanotic and acyanotic CHD [15]. The guidelines noted that children with CHD who
were most likely to benefit from immunoprophylaxis included those<12 months of age with
cyanotic heart disease, those receiving medication to control congestive heart failure, or those
with moderate-to-severe pulmonary hypertension. In 2014, the AAP guidance was updated to
recommend against RSV immunoprophylaxis in children with CHD in the second year of life
(ie, age 12–23 months at the start of the RSV season), asserting that these children are not at
increased risk of severe RSV infection [16]. In support of this decision, the Committee on
Infectious Diseases (COID) and Bronchiolitis Guidelines Committee policy statement cited an
analysis of Tennessee Medicaid data for children younger than 3 years, conducted from July
1989 to June 1993, that reported RSV hospitalization rates among children with any form of
CHD as 120.0 per 1000 children for children 0 to<6 months of age, 63.5 per 1000 children for
children 6 to<12 months of age, and 18.2 per 1000 children for children 12 to<24 months of
age. The RSV hospitalization rate for children with CHD at 12–23 months of age was less than
half the hospitalization rate for low-risk infants in the first 5 months after birth (44.1 per 1000)
[6, 16]. However, although all children with CHD have a lower risk of RSV hospitalization in
their second year of life, given the heterogeneity of CHD, it remains unclear whether specific
CHD diagnoses are associated with higher risk of hospitalization due to RSV during the sec-
ond year of life. This study was designed to investigate the risk of hospitalization due to RSV in
the second year of life by specific CHD diagnostic groups using a large, nationally representa-
tive database of US inpatient admissions.
RSV hospitalization risk in young children with CHD
PLOS ONE | DOI:10.1371/journal.pone.0172512 March 2, 2017 2 / 16
of AstraZeneca and hold stock or stock options.
PCW has received grant/research support through
his institution from AstraZeneca. The specific roles
of these authors are articulated in the ’author
contributions’ section. Editorial assistance was
provided by The Lockwood Group (Stamford, CT,
USA) and funded by AstraZeneca. Palivizumab is
marketed by MedImmune, a specialty care division
of AstraZeneca. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: This research was funded by
AstraZeneca. JF and XJ provided consultant/
research support for AstraZeneca. AB and CSA are
employees of AstraZeneca. Palivizumab is
marketed by MedImmune, a specialty care division
of AstraZeneca. This does not alter our adherence
to PLOS ONE policies on sharing data and
materials.
Materials and methods
Study design
Cohort and case-control studies were conducted using data from the 1997–2013 National
Inpatient Sample database to estimate RSV hospitalization rates at 12–23 months of age
among children diagnosed with various types of CHD [17]. The case-control approach was
considered the primary analysis for the estimate of the incidence of RSV hospitalization at 12–
23 months of age, owing to the recognized limitations of the cohort approach as detailed
below. The NIS is a 20% stratified sample of US inpatient admissions to US acute care hospitals
and has been previously used to examine national trends in health risks related to CHD [18].
Both clinical and non-clinical data elements for each hospital stay are available in the NIS,
including patient demographics, primary and secondary diagnoses and procedures, resource-
use information, and severity and comorbidity measures. National estimates can be calculated
using weighting provided by the Agency for Healthcare Research and Quality. The National
Inpatient Sample database is a publically available database, in which patient records are anon-
ymized and de-identified before public release. Analyses of de-identified data from the
National Inpatient Sample database are exempt from federal regulations for the protection of
human research participants. All procedures involving human participants and confidentiality
were reviewed and approved by the Research Ethics Review Board of the Agency for Health-
care Research and Quality.
Patient identification
Congenital heart defects were identified by the study physicians’ review of available ICD-9
codes and informed by the technical specifications of the pediatric heart surgery volume
quality indicator published by the Agency for Healthcare Research and Quality [19]. Because
many CHD diagnoses are extremely rare, the authors grouped defects that commonly occur
together, are difficult to distinguish from each other, and/or produce the same circulatory
effect (Table 1). Consistent with established standards in CHD surveillance [20], infants with a
code for preterm birth (ICD-9 765.0x, 765.1x, 765.20–765.28) or birthweight <2000 grams
(764.0x, 764.1x, 764.2x, and 764.9x with 5th digit from 0 to 7, or V2130, V2131, V2132, V2133,
V2134) were excluded from the birth cohort of infants with atrial septal defect or patent ductus
arteriosus. As noted in Table 1, five diagnostic groups were analyzed in the absence of other
CHD diagnoses due to a high coincidence with other CHD diagnoses.
Outcome measures and statistics
Patient demographics were described using summary statistics. Any hospitalization with at
least one of the three RSV-specific ICD-9 codes (ICD-9 480.1, 466.11, and 079.6) was catego-
rized as a hospitalization due to RSV. Although laboratory confirmation is unknown for cases
coded as RSV, a previous study demonstrated that these codes are specific for diseases related
to RSV [21]. As the most common disease associated with RSV in young children is bronchiol-
itis, hospitalizations coded as unspecified bronchiolitis (UB) were also evaluated as a compari-
son outcome. For this analysis, UB hospitalizations were those with a diagnosis code of 466.19
(acute bronchiolitis due to other infectious organisms) or 466.1 (acute bronchiolitis) without
any RSV-specific diagnostic code. Although UB-coded hospitalizations can include events due
to undiagnosed RSV, UB-coded events commonly represent bronchiolitis caused by pathogens
other than RSV [21].
Hospitalizations for RSV and UB were described by length of stay, use of mechanical venti-
lation, inpatient mortality, and total charges. Inpatient mortality (coded as “Died” in the
RSV hospitalization risk in young children with CHD
PLOS ONE | DOI:10.1371/journal.pone.0172512 March 2, 2017 3 / 16
National Inpatient Sample dataset) and mechanical ventilation use (procedure codes 9390,
9392, 9601, 9602, 9603, 9604, 9605, 9670, 9671, or 9672) were evaluated as a proportion of total
hospitalizations. Because length of hospitalization and total hospital charges were not normally
Table 1. ICD-9-CMa Codes for Conditions Associated With Congenital Heart Disease.
Conditions ICD-9-CM Average Annual Live
Births 1997–2013
Isolated patent ductus arteriosusb,c 747.0 8184
Unspecified congenital anomaly of heart, other specified
congenital anomaly of heart
746.89, 746.9 7770
Isolated unspecified defect of septal closure, ventricular
septal defectb
745.4, 745.9 7169
Isolated secundum atrial septal defect, partial anomalous
pulmonary venous returnb,c
745.5, 747.42 5544
Isolated pulmonary valve stenosis, congenital anomalies
of pulmonary artery, other congenital anomalies of
pulmonary valve, congenital pulmonary valve anomaly
unspecifiedb
746.00, 746.02,
746.09, 747.3
3286
Pulmonary valve atresia, tricuspid atresia, pulmonary
artery coarctation and atresia, other anomalies of
pulmonary artery and pulmonary circulation
746.01, 746.1,
747.31, 747.39
1331
Congenital anomalies of aortic arch with other congenital
anomalies of aorta, coarctation, interrupted aortic arch,
congenital anomaly of aorta unspecified
747.10, 747.11,
747.20, 747.21,
747.29
1231
Tetralogy of Fallot, infundibular pulmonic stenosis 745.2, 746.83 1088
Congenital mitral stenosis, congenital mitral regurgitation 746.5, 746.6 895
Congenital insufficiency of aortic valve 746.4 742
Other endocardial cushion defect, ostium primum defect,
unspecified
745.60, 745.61,
745.69
659
Subaortic stenosis, congenital atresia and stenosis of
aorta, congenital aortic stenosis, congenital obstructive
anomalies
746.3, 746.81,
746.84, 747.22
638
Congestive heart failure 428.0 537
Transposition of great vessels 745.10, 745.12
745.19
534
Hypoplastic left heart syndrome 746.7 523
Malposition of heart and cardiac apex with other
anomalies of great vessels (heterotaxia), congenital
anomalies of great veins
746.87, 747.40,
747.49
513
Double outlet right ventricle, other bulbus cordis
anomalies
745.11, 745.8 387
Common truncus 745.0 169
Ebstein’s anomaly 746.2 164
Cardiomyopathy 425.4 162
Congenital heart block 746.86 132
Common ventricle, cor biloculare 745.3, 745.7 125
Total anomalous pulmonary venous connection 747.41 109
Isolated coronary artery anomaly congenitalb 746.85 37
Cor triatriatum 746.82 14
a ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.
b Due to a high coincidence with other CHD diagnoses, these diagnostic groups were analyzed in the
absence of other CHD diagnoses.
c Excludes preterm births with atrial septal defect or patent ductus arteriosus.
doi:10.1371/journal.pone.0172512.t001
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distributed, geometric means were calculated. Total charges were inflation-adjusted to 2015
dollars [22].
For the cohort analysis, hospitalization rates were calculated using the weighted estimate of
hospitalizations for children 12–23 months of age and estimates of all infant birth hospitaliza-
tion discharges with CHD diagnoses for 1997–2013, excluding neonatal deaths. As the absolute
risks of RSV hospitalization are not robust due to limited testing and coding for RSV [23–25],
the relative risks (RR) of hospitalization for UB were calculated for children 12–23 months of
age with CHD diagnoses relative to those 12–23 months of age without CHD.
However, there are limitations with using a cohort design with birth hospitalization dis-
charge diagnoses as the denominator for RR calculations, as some forms of CHD are fre-
quently diagnosed only after the birth hospitalization and some may be diagnosed inaccurately
at birth [20]. CHD codes may not be assigned to all children with a past history of the condi-
tion during hospitalizations in the second year of life, particularly for CHD diagnoses that
have become clinically insignificant due to surgical intervention or clinical resolution, and no
data were available on mortality among children with CHD following the birth hospitalization.
As a result, a case-control analysis was also conducted using data exclusively collected for chil-
dren hospitalized at 12–23 months of age.
For the case-control analysis, for children with and without CHD, the odds of being hospi-
talized with RSV or UB were compared to the odds of having a hospitalization event expected
to have a similar incidence in children with and without CHD. ICD-9 codes for traumatic inju-
ries, burns, and poisonings (ICD-9 codes 800–999) were used as the comparison outcome,
excluding diagnoses that were found to be disproportionately more frequent among children
with CHD, specifically those related to surgical procedures or unspecified causes (ICD-9 codes
990–999), foreign bodies by mouth (ICD-9 codes 933–935), and femoral neck fractures (ICD-
9 code 820). Given the frequency of RSV hospitalization, the odds ratio (OR) should approxi-
mate the true RR among children diagnosed with CHD at 12–23 months of age. Because of the
known limitations of the cohort approach, the case-control approach was considered the pri-
mary analysis for the estimate of the incidence of RSV hospitalization at 12–23 months of age.
To examine temporal trends in the results, and given the small sample for many CHD diag-
nostic groups, the analysis was conducted separately and compared for 1997–2005 and 2006–
2013, based on dividing the total surveillance period at the mid-point. All data management
and analyses for this study were performed using SAS/STAT software, version 9.3 of the SAS
System (SAS Institute Inc., Cary, NC, USA), with statistical procedures that incorporated
weights to account for the structure of the sample survey data. Statistical significance was
assigned for a P value< .05.
Results
Over the 17-year period studied (1997–2013), a total of 1,168,886 live birth hospitalizations
with CHD ICD-9 codes were identified (annual average of 68,758 births). As expected, the
prevalence of CHD diagnoses varied considerably by diagnostic group, with patent ductus
arteriosus, unspecified anomaly, atrial septal defect, and ventricular septal defect representing
the most prevalent diagnoses (Table 1). The coincidence of CHD diagnostic groups is summa-
rized in S1 Table (live births) and S2 Table (children 12–23 months). The surveillance period
included 4,813 RSV hospitalizations among children 12–23 months of age with CHD. The pro-
portion of children with non-private insurance was higher among those with RSV hospitaliza-
tion at 12–23 months of age for children with and without CHD (both P< .01) compared to
the proportion among the live birth populations (Table 2). The proportion with Native Ameri-
can race (P< .01) was also higher among RSV-hospitalized infants compared to the birth
RSV hospitalization risk in young children with CHD
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population; whereas the proportion with White race (P = .04) was lower. The timing of RSV
hospitalization matched the known seasonality of RSV in the US [26].
Among CHD patients hospitalized for RSV disease at 12–23 months of age, the mean length
of stay was 4.5 days; 12% required mechanical ventilation, and 1.5% died (Table 3). Length of
stay and mechanical ventilation use varied considerably across diagnostic groups and were
highest among those with cardiomyopathy, congestive heart failure, and transposition of the
great vessels. Mean total hospitalization charges ($19,650) were significantly higher than those
observed in children without CHD ($7,939) (P< .01) and were higher in those conditions
with increased mean hospital lengths of stay. Inpatient mortality was highest among children
with transposition of the great vessels (10.2%), congestive heart failure (9.2%), cardiomyopathy
(9.2%), Ebstein’s anomaly (8.8%), and aortic stenosis (6.1%) (Table 4). Compared to children
12–23 months of age without CHD, children with Ebstein’s anomaly, transposition of the
great arteries, aortic stenosis, heterotaxia, and aortic arch anomalies had 367-fold, 344-fold,
203-fold, 117-fold, and 47-fold increased risk of RSV mortality, respectively (Table 4). Among
those with inpatient mortality, 87% required mechanical ventilation. For UB, mean hospital
lengths of stay were shorter and hospitalization costs were lower than for RSV hospitalization,
and mechanical ventilation use was less prevalent (Table 5). Inpatient mortality was rare and
Table 2. Characteristics of Hospitalized Patients 12–23 Months of Age in the NIS, 1997 to 2013.
With Any CHD Without CHD
Live
Births
All Age 12–23 Months
Hospitalizations
Age 12–23
Months RSVH
Live Births All Age 12–23 Months
Hospitalizations
Age 12–23
Months RSVH
Total
hospitalizations, n
1,168,886 99,621 4,813 65,333,543 3,085,545 224,044
Sex, % * *
Male 51.4 51.7 51.6 51.1 56.2 55.7
Female 48.6 48.3 48.4 48.8 43.7 44.3
Race or ethnic
group, %
* * * *
White 38.6 40.3 34.3 41.7 38.9 40.1
Black 15.0 12.2 15.5 10.4 14.5 12.7
Hispanic 20.0 16.5 20.2 16.9 15.5 15.4
Asian or Pacific
Islander
3.3 3.4 2.7 3.7 2.4 2.2
Native American 0.6 0.9 1.4 0.6 0.8 1.5
Other 4.3 4.4 3.5 4.2 4.1 3.8
Admission quarter,
%
* * * *
January–March 21.6 25.7 58.4 22.4 31.7 62.1
April–June 22.3 23.4 7.6 23.1 20.5 5.6
July–September 23.2 20.6 2.1 24.6 16.0 1.5
October–
December
22.3 21.3 22.9 23.1 22.2 23.6
Type of health
insurance, %
* * * *
Private 48.7 40.6 35.7 52.1 43.1 39.4
Other 51.1 59.2 64.2 47.7 56.6 60.3
RSVH, Respiratory Syncytial Virus Hospitalization.
*P < .05 compared to the proportion among live births.
doi:10.1371/journal.pone.0172512.t002
RSV hospitalization risk in young children with CHD
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significantly less frequent than with RSV; the only mortality events observed occurred among
children with heterotaxia or congestive heart failure (Table 4).
The OR of RSV hospitalization for children 12–23 months of age with CHD varied consid-
erably across the diagnostic groups, which are presented in order of decreasing association in
Fig 1. All CHD groups were associated with increased odds of RSV hospitalization, and the
Table 3. RSV Hospitalization Illness Severity Indicators for Children 12–23 Months of Age With and Without CHD, 1997–2013.
Conditiona 12–23 Months
RSVH, N
Meanb Days of
Stay (SE)
Percent of Mechanical
Ventilation Use (SE)
Meanb,c Total $
Charge (SE)
Transposition of great vessels 138 4.6 (1.3)* 30.7 (7.6) * 34485 (10757) *
Congestive heart failure 356 8.5 (1.4) * 33.9 (5.5) * 45631 (7702) *
Cardiomyopathy 156 6.2 (2.0) * 29.3 (9.2) * 34020 (9960) *
Ebstein’s anomaly 52 3.4 (0.6) * 8.8 (8.4) 15198 (4964) *
Subaortic stenosis, congenital atresia and stenosis of aorta, congenital
aortic stenosis, congenital obstructive anomalies
163 3.5 (0.4) * 6.1 (4.2) 13573 (2235) *
Malposition of heart and cardiac apex with other anomalies of great
vessels (heterotaxia), congenital anomalies of great veins
149 4.8 (1.7) * 19.7 (8.2) * 33365 (8618) *
Congenital anomalies of aortic arch with other congenital anomalies of
aorta, coarctation, interrupted aortic arch, congenital anomaly of aorta
unspecified
172 4.3 (0.8) * 16.8 (6.3) * 21082 (4576) *
Isolated patent ductus arteriosus 212 4.8 (0.7) * 13.8 (5.3) * 18921 (3445) *
Isolated secundum atrial septal defect, partial anomalous pulmonary
venous return
801 5.3 (0.4) * 15.1 (2.6) * 22502 (2375) *
Common ventricle, cor biloculare 63 6.6 (2.3) * 22.1 (12.4) * 31810 (15718) *
Total anomalous pulmonary venous connection 43 4.1 (1.6) 21.8 (18.2) * 24579 (15049)
Congenital insufficiency of aortic valve 113 4.6 (1.1) * 17.1 (7.8) * 14333 (3401) *
Other endocardial cushion defect, ostium primum defect, unspecified 186 7.1 (1.0) * 15.1 (5.1) * 30284 (6591) *
Congenital mitral stenosis, congenital mitral regurgitation 75 4.4 (0.9) * 12.7 (8.4) * 13892 (4244)
Tetralogy of Fallot, infundibular pulmonic stenosis 291 4.8 (0.8) * 11.4 (4.0) * 21317 (3616) *
Hypoplastic left heart syndrome 160 3.3 (0.8) 9.5 (4.8) * 17433 (3510) *
Unspecified congenital anomaly of heart, other specified congenital
anomaly of heart
641 3.7 (0.4) * 9.3 (2.6) * 16862 (1725) *
Pulmonary valve atresia, tricuspid atresia, pulmonary artery coarctation
and atresia, other anomalies of pulmonary artery and pulmonary
circulation
164 5.2 (0.7) * 8.1 (4.3) * 21389 (3688) *
Isolated pulmonary valve stenosis, congenital anomalies of pulmonary
artery, other congenital anomalies of pulmonary valve, congenital
pulmonary valve anomaly unspecified
172 4.7 (0.7) * 5.4 (3.7) 16372 (3643) *
Isolated unspecified defect of septal closure, ventricular septal defect 654 3.6 (0.2) * 5.3 (1.9) * 12950 (1287) *
Double outlet right ventricle, other bulbus cordis anomalies 102 4.9 (1.3) * 4.4 (4.3) 21092 (6705) *
Common truncus 18 6.1 (1.8) * 0 32164 (16986) *
All CHD 4813 4.5 (0.2) * 12.3 (1.2) * 19650 (993) *
Without CHD 224,044 2.3 (0.02) 2.3 (0.1) 7939 (138)
Individual diagnostic groups are ordered in descending order first based on the frequency of inpatient mortality and second by the frequency of mechanical
ventilation. ASD, atrial septal defect; CHD, congenital heart disease; NE, not estimable due to no reported injury/poisoning hospitalizations; RSV,
respiratory syncytial virus;RSVH, respiratory syncytial virus hospitalization.
a No results are shown for diagnostic groups with10 RSV hospitalization identified, consistent with Healthcare Cost and Utilization Project guidelines for
National Inpatient Sample database analyses.
b Geometric mean.
c Adjusted to 2015 US dollars.
*P < .05 compared to the population without CHD.
doi:10.1371/journal.pone.0172512.t003
RSV hospitalization risk in young children with CHD
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OR for all CHD diagnoses was 3.5. Fourteen groups had an OR of3.5. No OR was estimable
for Ebstein’s anomaly because there were no injury/poisoning hospitalizations reported. By
diagnostic group, results by RR and OR were generally similar. The OR and RR of UB hospital-
ization by diagnostic group were generally similar to those observed with RSV (Fig 1).
When the intervals of 1997–2005 and 2006–2013 were analyzed separately, results were
generally similar. A similar number of RSV hospitalizations among children with CHD
occurred in both intervals (2361 and 2452, respectively). Among all RSV hospitalizations in
children with CHD, the proportion with inpatient mortality was decreased (1.8% to 1.2% in
1997–2005 and 2006–2013, respectively), whereas, there were increases in the proportion with
mechanical ventilation (10.1% to 14.5%), mean length of stay (4.3 to 4.8 days), and mean char-
ges ($15,202 to $25,239 for CHD versus $6,777 to $9,392 for non-CHD, all in 2015 US dollars).
The decline in RSV hospitalization mortality frequency was driven by a lack of reported mor-
tality during 2006–2013 for aortic arch anomalies, heterotaxia, and isolated patent ductus arte-
riosus; RSV mortality frequency in other conditions was similar in both intervals. The OR of
RSV hospitalization among all children with CHD was similar in both intervals, at 3.4 and 3.5,
respectively. By individual CHD diagnostic groups, OR estimates declined among several
higher-risk conditions, most notably aortic stenosis, congenital aortic arch anomalies, and pul-
monary valve/artery anomalies. Similar trends were observed in UB, with the additional obser-
vation of an increase in the OR for UB hospitalization among all CHD children from 2.7 to
3.7.
Table 4. Percent Inpatient Mortality Among Children 12–23 Months of Age Hospitalized with RSV or
UB, 1997–2013.
Conditiona Percent of Inpatient
Mortality (SE)
RSV UB
Transposition of great vessels 10.2 (5.3) * 0
Congestive heart failure 9.2 (3.7) * 2.5 (1.8) *
Cardiomyopathy 9.2 (5.1) * 0
Ebstein’s anomaly 8.8 (8.4) * 0
Subaortic stenosis, congenital atresia and stenosis of aorta, congenital aortic
stenosis, congenital obstructive anomalies
6.1 (4.2) * 0
Malposition of heart and cardiac apex with other anomalies of great vessels
(heterotaxia), congenital anomalies of great veins
3.1 (3.1) * 3.4 (3.4) *
Congenital anomalies of aortic arch with other congenital anomalies of aorta,
coarctation, interrupted aortic arch, congenital anomaly of aorta unspecified
2.6 (2.6) * 0
Isolated patent ductus arteriosus 2.4 (2.3) * 0
Isolated secundum atrial septal defect, partial anomalous pulmonary venous
return
1.1 (0.8) * 0
All CHD 1.5 (0.4) * 0.3 (0.2) *
Without CHD 0.1 (0.02) 0.02
(0.01)
Individual diagnostic groups are ordered in descending order based on the frequency of inpatient mortality
and secondarily the frequency of mechanical ventilation. Diagnostic groups are not listed if no mortality was
observed with RSV or UB. ASD, atrial septal defect; CHD, congenital heart disease; RSV, respiratory
syncytial virus; RSVH, respiratory syncytial virus hospitalization; UB, unspecified bronchiolitis.
a No results are shown for diagnostic groups with10 RSV hospitalization identified, consistent with
Healthcare Cost and Utilization Project guidelines for National Inpatient Sample database analyses.
*P < .05 compared to the population without CHD
doi:10.1371/journal.pone.0172512.t004
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Discussion
Despite the previous observation that overall RSV hospitalization rates among children with
CHD are lower at 12–23 months of age relative to children with CHD at 0–11 months of age
[6], the present study demonstrates that compared to children without CHD, multiple specific
CHD diagnoses are associated with substantial risks of mechanical ventilation and inpatient
Table 5. UB Hospitalization Illness Severity Indicators for Children 12–23 Months of Age With CHD and Without CHD, 1997–2013.
Conditiona 12–23 Months
RSVH, N
Meanb Days of
Stay (SE)
Percent of Mechanical
Ventilation Use (SE)
Meanb,c Total $
Charge (SE)
Transposition of great vessels 71 3.5 (0.9) * 13.3 (9.0) * 17066 (5172) *
Congestive heart failure 304 4.1 (0.5) * 4.2 (2.4) * 16800 (2371) *
Cardiomyopathy 125 2.9 (0.9) 8.2 (5.3) * 12626 (2791) *
Ebstein’s anomaly 50 2.1 (1.2) 0 10249 (2268) *
Subaortic stenosis, congenital atresia and stenosis of aorta, congenital
aortic stenosis, congenital obstructive anomalies
94 3.7 (0.9) * 21.0 (9.4) * 18695 (5491) *
Malposition of heart and cardiac apex with other anomalies of great
vessels (heterotaxia), congenital anomalies of great veins
146 2.8 (0.9) 27.4 (8.2) * 21086 (5169) *
Congenital anomalies of aortic arch with other congenital anomalies of
aorta, coarctation, interrupted aortic arch, congenital anomaly of aorta
unspecified
157 3.1 (0.7) * 12.0 (5.4) * 19525 (2883) *
Isolated patent ductus arteriosus 168 2.4 (0.7) 8.6 (4.8) * 12984 (2489) *
Isolated secundum atrial septal defect, partial anomalous pulmonary
venous return
575 3.9 (0.5) * 11.0 (3.0) * 18055 (1919) *
Common ventricle, cor biloculare 22 4.5 (1.6) * 20.3 (18.2) * 20230 (13404)
Total anomalous pulmonary venous connection 29 5.0 (1.5) * 15.1 (14.4) * 22344 (9546) *
Congenital insufficiency of aortic valve 117 2.8 (0.4) * 0 13609 (2593) *
Other endocardial cushion defect, ostium primum defect, unspecified 116 3.6 (0.8) * 4.3 (4.3) 15032 (4425) *
Congenital mitral stenosis, congenital mitral regurgitation 74 3.3 (0.9) * 0 15368 (4840) *
Tetralogy of Fallot, infundibular pulmonic stenosis 269 3.3 (0.3) * 0 10322 (1368) *
Hypoplastic left heart syndrome 166 4.2 (0.6) * 5.7 (3.8) * 20261 (3922) *
Unspecified congenital anomaly of heart, other specified congenital
anomaly of heart
601 2.7 (0.3) * 6.5 (2.1) * 12415 (1288) *
Pulmonary valve atresia, tricuspid atresia, pulmonary artery coarctation
and atresia, other anomalies of pulmonary artery and pulmonary
circulation
154 3.3 (0.9) * 14.4 (6.3) * 20654 (5574) *
Isolated pulmonary valve stenosis, congenital anomalies of pulmonary
artery, other congenital anomalies of pulmonary valve, congenital
pulmonary valve anomaly unspecified
157 2.1 (0.5) 3.2 (3.1) 10631 (1820) *
Isolated unspecified defect of septal closure, ventricular septal defect 405 2.3 (0.3) * 7.0 (2.6) * 10354 (1234) *
Double outlet right ventricle, other bulbus cordis anomalies 84 4.1 (1.1) * 22.5 (9.9) * 21143 (7852) *
Common truncus 38 3.6 (1.2) * 9.8 (8.4) * 13099 (5168)
All CHD 3,754 3.0 (0.1) * 7.4 (0.9) * 13867 (629) *
Without CHD 190,276 1.7 (0.02) 1.1 (0.1) 6570 (98)
To aid in comparison of results, individual diagnostic groups are ordered in descending order based on the frequency of RSV inpatient mortality and
secondarily the frequency of RSV mechanical ventilation. CHD, congenital heart disease; NE, not estimable due to no reported injury/poisoning
hospitalizations; RSVH, respiratory syncytial virus hospitalization; UB, unspecified bronchiolitis.
a No results are shown for diagnostic groups with10 RSV hospitalization identified, consistent with Healthcare Cost and Utilization Project guidelines for
National Inpatient Sample analyses.
b Geometric mean.
c Adjusted to 2015 US dollars.
*P < .05 comparing to the population without CHD
doi:10.1371/journal.pone.0172512.t005
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Fig 1. OR and RR of RSV or UB Hospitalization for Children 12–23 Months of Age With CHD by Diagnostic Group.
doi:10.1371/journal.pone.0172512.g001
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mortality as well as an increased risk of RSV hospitalization at 12–23 months of age with
increased mean lengths of stay and total charges during RSV hospitalization. Five conditions
(Ebstein’s anomaly, transposition of the great arteries, aortic stenosis, heterotaxia, and aortic
arch anomalies) demonstrated a substantially elevated risk of RSV mortality, and 14 were asso-
ciated with an elevated incidence of RSV hospitalization. The results from the present study
provide clear evidence that for children with these high-risk types of CHD, RSV lower respira-
tory tract illness continues to be an important risk to their health through the second year of
life. The results for RSV hospitalization are substantiated by the finding of similar results for
UB hospitalizations and similar results when comparing 1997–2005 and 2006–2013. However,
the lower severity of UB hospitalizations, as measured by length of stay, mechanical ventilation
use, and inpatient mortality, highlights the more deleterious effects of RSV-specific disease in
this population.
The current results are supported by the findings of Li et al. (2016), which compared patient
characteristics and outcomes of children with hemodynamically significant CHD who received
palivizumab and were enrolled in a large Canadian registry from 2005 to 2015.[27] Children
receiving palivizumab in the second year of life represented a higher-risk subset of those re-
ceiving it in the first year, as only 28% of first year recipients continued for a second year and
these infants had a much more complicated neonatal course. When outcomes were evaluated,
the first and second year cohorts had similar hazards of RSV and overall respiratory-related ill-
ness hospitalizations, consistent with the present finding of significantly elevated risk among a
high-risk subset of CHD patients in the second year of life.
The current analysis demonstrates that the previous observation of overall lower risk for all
CHD patients in the second year of life is driven by the relatively low risk associated with the
most prevalent conditions, such as isolated ventricular septal defect and patent ductus arterio-
sus. However, when the data are examined more closely, all of the diagnostic groups associated
with a substantially increased risk of severe RSV disease represent hemodynamically signifi-
cant CHD, including cyanotic heart disease, moderate-to-severe pulmonary hypertension, and
acyanotic defects requiring medication or surgery—the same risk factors that identify those
CHD patients most likely to benefit from immunoprophylaxis in the first year of life [15].
It should be noted that the impact of RSV on CHD patients hospitalized for RSV disease at
12–23 months of age is not merely confined to morbidity and mortality. In the more recent
estimates from 2006–2013, there was a substantial increase in mean hospitalization charges for
RSV in CHD ($25,239) versus non-CHD patients ($6,777), with even higher estimates among
those with more severe CHD. This underlines the increased financial burden of RSV disease
for CHD patients in the second year of life.
RSV immunoprophylaxis recommendations for children with CHD who are 12–23 months
of age at the start of RSV season differ worldwide. Recommendations in Spain [28], the Neth-
erlands [29], and Japan [30] support immunoprophylaxis for all children with hemodynami-
cally significant CHD24 months of age at RSV season start. Germany employs a risk-based
approach, recommending immunoprophylaxis for those at 12–23 months of age with a “mod-
erate risk” of RSV hospitalization [31]. Guidance in the United Kingdom [32] and Sweden
[33] recommend immunoprophylaxis for children at 12–23 months of age with specific CHD
diagnoses, such as CHD with pulmonary hypertension, congestive heart failure, or those with
single ventricles. In contrast, guidance in Canada [34], Italy [35], and South Korea [8] does not
recommend immunoprophylaxis for children with CHD at 12–23 months of age.
The observation for some CHD conditions of higher risks based on the RR approach versus
the OR approach is likely due to under-diagnosis of some CHD conditions at birth. This was
particularly pronounced for congestive heart failure and cardiomyopathy, both of which may
be more frequently diagnosed following the birth hospitalization. Conversely, a higher risk by
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the OR versus RR may be due to over-diagnosis of CHD conditions at birth, perhaps due to
ICD-9 coding of suspected but not yet confirmed diagnoses. In the present analysis, we found
that double outlet right ventricle, endocardial cushion/ostium primum defects, Tetralogy of
Fallot, and hypoplastic left heart syndrome commonly were diagnosed simultaneously among
birth hospitalizations, consistent with the potential of over-diagnosis of some CHD conditions
at birth before a precise diagnosis is established. ICD-9 coding should be more accurate at 12–
23 months of age compared to the birth hospitalization [20, 36]. Additionally, the higher risk
by OR could be due to less prevalent use of CHD codes among children after surgical correc-
tion or clinical resolution of their disease. The elevated risks by the case-control approach for
these diagnostic groups are consistent with a significantly elevated risk among children with
continuing CHD pathology.
The case-control analysis relies on the assumption that CHD codes are equally prevalent
among hospitalizations for RSV or UB relative to those for injuries and poisonings. Differen-
tial use of CHD codes for RSV or UB versus injuries and poisoning would skew the OR esti-
mates. However, the high prevalence of less severe CHD codes (eg, isolated patent ductus
arteriosus) reported for children 12–23 months of age hospitalized with injuries and poison-
ings suggests that reporting of CHD codes in children with a history of CHD is commonplace,
even for non-cardiopulmonary hospitalizations. Additionally, the incidence of injuries and
poisonings among children 12–23 months of age with CHD could be decreased due to reduced
activity or increased due to increased risks of metabolic bone disease [37], physical abuse [38],
or drug-related adverse events [39]. The decreased or increased incidence of injury/poisoning
among children with CHD would lead to an overestimate and underestimate of the OR for
RSV hospitalization, respectively. However, the finding that the specific injury/poisoning
ICD-9 codes employed in the analysis occurred at a similar proportional frequency among
CHD and non-CHD children supports the validity of the OR analysis. Further, collectively the
above factors did not appear to have a significant impact on the results, given that the RR and
OR estimates of risk are similar in many diagnostic groups and the overall OR for all CHD at
12–23 months of age is similar to the previous observation by Boyce et al. [6].
Strengths of the current analysis relate to use of 17 years of data from a large, nationally rep-
resentative database of US hospitalizations. This large sample size enabled a robust examina-
tion of RSV and UB hospitalization illness severity and risk by individual CHD diagnostic
groups, many of which are extremely rare. Additionally, the estimation of hospitalization risks
using both cohort and case-control designs helped to address limitations inherent in both
approaches. The fact that similar results were observed using the two methods for most condi-
tions supports the validity of the current findings.
Limitations of the current study include the following: Data from the NIS database do not
enable identification of which patients had received RSV immunoprophylaxis. Selective use of
RSV immunoprophylaxis during many of the years studied may have reduced the overall inci-
dence of RSV hospitalization among the CHD population [40, 41], although it is likely that not
all high risk children 12–23 months of age with CHD received immunoprophylaxis [42]. Simi-
larly, no patient-level data were available on the status of surgical correction for the hospital-
ized children. This would be expected to influence the risk profile of certain patient subgroups
because surgically repaired patients should no longer be at high risk once recovered from sur-
gery. Therefore, these analyses and conclusions are conservative, with the current results rep-
resenting the risk associated with all infants with a diagnostic code of the condition, including
those with and without surgical correction. Not all cardiac surgery for CHD is performed in
the first year of life. The Agency for Healthcare Research and Quality has documented the age
at which major CHD surgeries are performed in US children, demonstrating that 23% occur
during the neonatal period, 38% from 1–11 months of age, 14% from 12–23 months of age, 9%
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from 3–5 years of age, 10% from 6–12 years of age, and 6% from 13–17 years of age [43]. There-
fore, the finding that 39% of major pediatric surgeries for CHD are conducted after 11 months
of age would suggest that some children with severe CHD continue to have pathophysiology
that would place them at increased risk for severe RSV disease at 12–23 months of age.
Conclusions
Using data from a nationally representative database from a period of 17 years, this study
found that certain CHD diagnoses place children at an elevated risk of RSV hospitalization at
12–23 months of age with considerable hospital morbidity and mortality. The highest-risk
CHD diagnoses fit the definition of hemodynamically significant CHD, and such patients
would benefit from all efforts to prevent the incidence of severe RSV disease in the second year
of life.
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